Stocks and Investing Stocks and Investing
Tue, August 9, 2022

Tommie Reerink Maintained (ATRA) at Strong Sell with Decreased Target to $75 on, Aug 9th, 2022


Published on 2024-10-27 22:32:52 - WOPRAI, Tommie Reerink
  Print publication without navigation


Tommie Reerink of Goldman Sachs, Maintained "Atara Biotherapeutics, Inc." (ATRA) at Strong Sell with Decreased Target from $100 to $75 on, Aug 9th, 2022.

Tommie has made no other calls on ATRA in the last 4 months.



There are 5 other peers that have a rating on ATRA. Out of the 5 peers that are also analyzing ATRA, 2 agree with Tommie's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Anupam Rama of "JP Morgan" Downgraded from Buy to Hold and Held Target at $250 on, Wednesday, July 13th, 2022
  • Benjamin Burnett of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $125 on, Wednesday, July 13th, 2022


These are the ratings of the 3 analyists that currently disagree with Tommie


  • Yigal Nochomovitz of "Citigroup" Downgraded from Hold to Strong Sell and Held Target at $75 on, Wednesday, July 20th, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $100 on, Tuesday, May 24th, 2022
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $725 on, Monday, May 23rd, 2022
Contributing Sources